Gene Delivery and Gene Editing (Focus Group - GDGE)

(200) LNP-Exosome Hybrid System for Targeted KRASG12D siRNA Delivery in Pancreatic Cancer Therapy

Introduction:

Pancreatic cancer (PDAC) has a poor prognosis, with a 5-year survival rate below 7%. KRAS mutations drive tumor progression and chemotherapy resistance. Small molecule inhibitors targeting KRAS have shown limited success. RNA interference (RNAi) using siRNA is a promising approach but suffers from delivery challenges. We developed an LNP-exosome hybrid system (HLNP) for targeted KRASG12D silencing and gemcitabine prodrug co-delivery. HLNP enhances gene delivery, reduces cancer cell viability, and synergizes KRAS silencing with chemotherapy, offering a potential PDAC treatment strategy.

Learning Objectives:

Upon completion, participants will be able to understand the concept of LNP-Exosome hybridization.
Upon completion, participants will be able to understand targeted gene therapy for pancreatic cancer
Upon completion, participants will be able to understand synergy effect between gemcitabine and KRAS

Poster Presenter(s)

Heewon Park, n/a

Postdoctoral researcher
Korea Advanced Institute of Science and Technology
Daejeon, Republic of Korea